Valneva shares plunge 37% on Lyme vaccine trial miss
Phase 3 study fails primary endpoint despite 73% efficacy in secondary analysis, casting doubt on approval timeline
Valneva shares collapsed 37.5% to $6.45 on Monday after the French vaccine maker and its partner Pfizer announced that their late-stage Lyme disease vaccine failed to meet its primary statistical endpoint, despite demonstrating strong efficacy in secondary analyses.
The steep decline erased roughly $543 million from Valneva's market capitalization, bringing it to approximately $913 million. The stock, which now trades near its 52-week low of $5.43, was among the worst performers in the biotechnology sector following the announcement.
The Phase 3 VALOR trial evaluated VLA15, a vaccine candidate co-developed with Pfizer, in participants aged 5 years and older. According to the companies' joint press release, the study's primary endpoint was not met in the initial analysis due to fewer Lyme disease cases being accrued than anticipated.
However, a secondary analysis revealed what the companies described as "clinically meaningful efficacy." The vaccine demonstrated a 73.2% reduction in confirmed Lyme disease cases compared to placebo from 28 days post-dose 4 in season 2, with a 95% confidence interval of 15.8 to 93.5. A separate analysis from one day post-dose 4 showed 74.8% efficacy, with a 95% confidence interval of 21.7 to 93.9.
Despite the primary endpoint miss, Pfizer expressed confidence in the vaccine's potential and plans to proceed with submissions to regulatory authorities, including the U.S. Food and Drug Administration and European Medicines Agency, in 2026.
The mixed results have created significant uncertainty around the approval timeline. While secondary endpoint data showed promising efficacy, the failure to meet the prespecified primary statistical criterion raises questions about regulatory acceptance and the strength of the data package.
Valneva, headquartered in Saint-Herblain, France, specializes in vaccines for infectious diseases with unmet medical needs. The company reported $180 million in revenue over the trailing 12 months but remains unprofitable, with a negative profit margin of 56.8% and earnings per share of -$1.49.
The Lyme disease vaccine represents a critical growth driver for Valneva, which has struggled financially. According to market data, analysts had previously viewed VLA15 as the sole late-stage Lyme disease vaccine candidate, giving Valneva a potential first-mover advantage in a market with significant unmet need.
Lyme disease, transmitted through tick bites, affects approximately 476,000 people annually in the United States and Europe combined, according to public health data. No vaccine has been approved for human use since the previous Lyme vaccine was withdrawn from the market in 2002 due to concerns about side effects and limited demand.
Pfizer's continued commitment to the regulatory submission process provides some offset to the negative market reaction. The pharmaceutical giant's involvement lends credibility to the program and suggests that despite the statistical setback, the vaccine's efficacy profile may still support approval.
However, analysts will now reassess Valneva's pipeline value and commercial prospects. Prior to the trial readout, Wall Street analysts had assigned bullish ratings to the stock, with price targets averaging approximately $13.10—more than double the current share price. The sharp sell-off reflects investor concern that the primary endpoint failure could delay approval, limit commercial uptake, or require additional clinical work.
Technical indicators highlight the stock's severe weakness. Valneva is currently trading 40.4% below its 20-day simple moving average and 31.9% below its 100-day average, according to market analysis. Key resistance sits at $7.00, while immediate support is at $6.00, with the 52-week low of $5.43 providing the next downside floor.
For investors, the coming weeks will be critical as Pfizer and Valneva engage with regulators to determine the path forward. The companies' decision to proceed with submissions suggests they believe the secondary efficacy data provides a sufficient basis for approval, but the market's reaction indicates substantial skepticism about the likelihood of success.
The Valneva case underscores the binary nature of biotech investing, where clinical trial results can drive dramatic share price swings. For now, the company's fate rests largely with regulators' interpretation of the mixed Phase 3 data and Pfizer's continued commitment to advancing the vaccine through the approval process.